IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.

Antib Ther · 2026 · PMC12967328 · PMID 41804385

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Importantly, high-dose IMM2510 outperformed both monotherapies and showed a trend toward superior efficacy compared to the VEGFR1-Fc plus atezolizumab combination ( Fig. 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.